PMID: 8968731Nov 1, 1996Paper

Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study

The Histochemical Journal
A SchotteJ E Leysen

Abstract

[3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin was used as a radioligand for the autoradiographic measurements of dopamine D3 receptors in rat and human brain. Preincubation of the brain sections was necessary to obtain binding of the radioligand in the islands of Calleja and in the nucleus accumbens, but not in cerebellar lobules 9/10 of the rat. D3 receptors were also totally occluded in unwashed sections of the human striatum. The radioligand binding to D3 receptors was maximal after preincubating the sections for at least 10 min. Pretreatment of the animals with reserpine or tetrabenazine, which results in a severe depletion of endogeneous monoamines, strongly reduces the occlusion of D3 receptors in unwashed brain sections. The occlusion of dopamine D3 receptors in brain sections suggests that the in vivo access to D3 receptors may be locally inhibited by endogenous dopamine. The in vitro binding affinities of 12 antipsychotic drugs for D2 and D3 receptors were evaluated in competition binding experiments, using both rat and cloned human receptors. Most of the compounds showed only a slightly lower affinity for D3 than for D2 receptors in vitro. Affinities of the antipsychotic drugs for cloned human D21 and D3 receptors wer...Continue Reading

References

Jan 11, 1979·Nature·J W Kebabian, D B Calne
Dec 1, 1992·European Journal of Pharmacology·A M MurrayJ N Joyce
Mar 1, 1992·Neurochemistry International·G MengodJ M Palacios
Aug 6, 1992·European Journal of Pharmacology·A SchotteJ E Leysen
Sep 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D LévesqueP Sokoloff
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1987·Computers in Biology and Medicine·E G Oestreicher, G F Pinto
Dec 3, 1984·Life Sciences·J C Stoof, J W Kebabian
Apr 1, 1993·Brain Research. Molecular Brain Research·B LandwehrmeyerJ M Palacios
Aug 1, 1993·Clinical Neuropharmacology·J C SchwartzP Sokoloff
Apr 22, 1993·European Journal of Pharmacology·M P KungC Foulon

❮ Previous
Next ❯

Citations

Nov 7, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Gerhard GrossKarla U Drescher
Jun 25, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Shinichiro NakajimaAriel Graff-Guerrero
Apr 23, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Patrick N McCormickAlan A Wilson
Mar 25, 2009·Pharmacology & Therapeutics·Sarah Grimwood, Paul R Hartig
Sep 1, 2011·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Paul ShotboltEugenii A Rabiner
Oct 10, 2014·Psychiatry and Clinical Neurosciences·Ichiro KusumiYoshito Takahashi
Apr 11, 2014·Drug and Alcohol Dependence·David MatuskeyYu-Shin Ding
Apr 16, 2010·The International Journal of Neuropsychopharmacology·Ingo VernalekenGerhard Gründer
Nov 29, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·Olaf PranteAshutosh Banerjee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.